NEW YORK, July 4, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Biogen Idec Inc. (NASDAQ: BIIB), Amgen, Inc. (NASDAQ: AMGN), Illumina, Inc. (NASDAQ: ILMN) and MannKind Corporation (NASDAQ: MNKD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4444-100free.
--
Gilead Sciences, Inc. Analyst Notes
On June 27, 2014, Gilead Sciences, Inc. (Gilead) announced that it has submitted a New Drug Application (NDA) to Japan's Pharmaceutical and Medical Devices Agency (PMDA) for approval of sofosbuvir, a once-daily nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection. The data in the NDA support the use of sofosbuvir with ribavirin (RBV) for 12 weeks in patients with genotype 2 HCV infection. "There is an urgent need in Japan for new HCV treatment options that are more effective, well-tolerated and simpler for patients," said Norbert Bischofberger, PhD, Executive Vice President of Research and Development and Chief Scientific Officer at Gilead. "Based on Phase 3 studies, we believe that sofosbuvir has the potential to provide high cure rates among genotype 2 patients in just 12 weeks of interferon-free therapy." The full analyst notes on Gilead are available todownload free of charge at:
http://www.analystsreview.com/Jul-04-2014/GILD/report.pdf
--
Biogen Idec Inc. Analyst Notes
On June 30, 2014, Biogen Idec Inc. (Biogen Idec) announced that it intends to report its Q2 2014 financial results on July 23, 2014, before the financial markets open. Following the results release, the Company will also host a conference call at 9:00 am ET to discuss its performance. The full analyst notes on Biogen Idec are available to download free of charge at:
http://www.analystsreview.com/Jul-04-2014/BIIB/report.pdf
--
Amgen, Inc. Analyst Notes
On July 1, 2014, Amgen, Inc. (Amgen) announced that the FDA has granted Breakthrough Therapy Designation to the Company's investigational bispecific T cell engager (BiTE) antibody blinatumomab. The Company informed that FDA's Breakthrough Therapy Designation was based on the results of a Phase 2 trial of 189 adult patients with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) treated with blinatumomab. "There is a high unmet need for new medicines to treat relapsed and refractory ALL patients, who have very few treatment options," said Sean E. Harper, M.D., Executive Vice President of Research and Development at Amgen. "The results from the Phase 2 trial evaluating blinatumomab in adult patients with relapsed or refractory ALL are encouraging and provide a strong basis for a regulatory filing later this year and potential approval in this serious disease." The full analyst notes on Amgen are available to download free of charge at:
http://www.analystsreview.com/Jul-04-2014/AMGN/report.pdf
--
Illumina, Inc. Analyst Notes
On June 30, 2014, Illumina, Inc. (Illumina) announced that it has entered into separate agreements with Biomnis, Genoma, and the Center for Human Genetics and Laboratory Diagnostics Martinsried, under which they will use the HiSeq 2500 and consumables from Illumina to develop and perform non-invasive prenatal testing (NIPT). "These agreements are another step in establishing Illumina as a global leader in reproductive and genetic health solutions and as a valued partner for NGS-based testing across a broad range of clinical applications," said Tristan Orpin, Senior Vice President and General Manager of Reproductive and Genetic Health at Illumina. The full analyst notes on Illumina are available to download free of charge at:
http://www.analystsreview.com/Jul-04-2014/ILMN/report.pdf
--
MannKind Corporation Analyst Notes
On June 27, 2014, MannKind Corporation (MannKind) announced that it has received FDA approval for AFREZZA (insulin human) Inhalation Powder to improve glycemic control in adult patients with diabetes mellitus. "We are excited for patients, as we believe that AFREZZA's distinct profile and non-injectable administration will address many of their unmet needs for mealtime insulin therapy, and has the potential to change the way that diabetes is treated. We thank the more than 6,500 adult patients and healthy volunteers who participated in the AFREZZA clinical program," said Alfred Mann, CEO of MannKind. The full analyst notes on MannKind are available to download free of charge at:
http://www.analystsreview.com/Jul-04-2014/MNKD/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
